Foster Dykema Cabot & Partners’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$144K Hold
5,130
0.01% 131
2025
Q4
$128K Buy
5,130
+60
+1% +$1.51K 0.01% 146
2025
Q3
$129K Sell
5,070
-1,625
-24% -$40.1K 0.01% 155
2025
Q2
$162K Hold
6,695
0.01% 138
2025
Q1
$170K Hold
6,695
0.01% 129
2024
Q4
$178K Sell
6,695
-164
-2% -$4.45K 0.01% 133
2024
Q3
$198K Sell
6,859
-736
-10% -$21.5K 0.02% 128
2024
Q2
$213K Sell
7,595
-192
-2% -$5.29K 0.02% 94
2024
Q1
$216K Buy
7,787
+1,076
+16% +$29.9K 0.02% 97
2023
Q4
$193K Buy
+6,711
New +$203K 0.02% 92

Other funds holding PFE

Foster Dykema Cabot & Partners's PFE Position: Q1 2026 in Review

Foster Dykema Cabot & Partners held its Pfizer (PFE) position steady in Q1 2026 at 5,130 shares worth $144K. The position accounts for 0.01% of the portfolio, ranked #131.

Foster Dykema Cabot & Partners first reported a position in PFE in Q4 2023 and has held it in 10 quarters since. The position peaked at $216K in Q1 2024. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Foster Dykema Cabot & Partners held 5,130 shares of Pfizer worth $144K as of Q1 2026.
  • Foster Dykema Cabot & Partners left its Pfizer share count unchanged in Q1 2026.
  • Pfizer made up 0.01% of Foster Dykema Cabot & Partners's portfolio in Q1 2026, its #131 holding.
  • Foster Dykema Cabot & Partners first reported a position in Pfizer in Q4 2023 and has held it in 10 quarters since.
  • Foster Dykema Cabot & Partners's Pfizer position peaked at $216K in Q1 2024.
  • 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Foster Dykema Cabot & Partners's 13F filing for Q1 2026, filed 14 May 2026.